1. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369:2106-2120.
2. Matthay KK, Maris JM, Schleiermacher G, et al. Neuroblastoma. Nat Rev Dis Primers. 2016;2:16078.
3. Nakagawara A, Li Y, Izumi H, Muramori K, Inada H, Nishi M. Neuroblastoma. Jpn J Clin Oncol. 2018;48:214-241.
4. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the interna- tional criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466-1477.
5. Cohn SL, Pearson ADJ, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2009;27:289-297.
6. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003;3:203-216.
7. Boon K, Caron HN, van Asperen R, et al. N-myc enhances the ex- pression of a large set of genes functioning in ribosome biogenesis and protein synthesis. EMBO J. 2001;20:1383-1393.
8. Valentijn LJ, Koster J, Haneveld F, et al. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplifi- cation. Proc Natl Acad Sci USA. 2012;109:19190-19195.
9. Wilson PM, Danenberg PV, Johnston PG, Lenz H-J, Ladner RD. Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. Nat Rev Clin Oncol. 2014;11:282-298.
10. Mathews CK. Deoxyribonucleotide metabolism, mutagenesis and cancer. Nat Rev Cancer. 2015;15:528-539.
11. Lau DT, Flemming CL, Gherardi S, et al. MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neu- roblastoma. Oncotarget. 2015;6:15510-15523.
12. Peng M, Litman R, Xie J, Sharma S, Brosh RM, Cantor SB. The FANCJ/MutLalpha interaction is required for correction of the cross-link response in FA-J cells. EMBO J. 2007;26:3238-3249.
13. Santiago Y, Chan E, Liu P-Q, et al. Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleases. PNAS. 2008;105:5809-5814.
14. Liu P-Q, Chan EM, Cost GJ, et al. Generation of a triple-gene knock- out mammalian cell line using engineered zinc-finger nucleases. Biotechnol Bioeng. 2010;106:97-105.
15. Zhang Q, Shen J, Wang H, et al. TS mRNA levels can predict peme- trexed and raltitrexed sensitivity in colorectal cancer. Cancer Chemother Pharmacol. 2014;73:325-333.
16. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell. 2003;3:421-429.
17. Byrne BM, Oakley GG. Replication protein A, the laxative that keeps DNA regular: the importance of RPA phosphorylation in maintaining genome stability. Semin Cell Dev Biol. 2019;86:112-120.
18. Dominguez-Sola D, Gautier J. MYC and the control of DNA replica- tion. Cold Spring Harb Perspect Med. 2014;4:a014423.
19. Petroni M, Sardina F, Infante P, et al. MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors. Cell Death Dis. 2018;9:895-912.
20. Colicchia V, Petroni M, Guarguaglini G, et al. PARP inhibitors en- hance replication stress and cause mitotic catastrophe in MYCN- dependent neuroblastoma. Oncogene. 2017;36:4682-4691.
21. Saito K, Nagashima H, Noguchi K, et al. First-in-human, phase I dose-escalation study of single and multiple doses of a first- in-class enhancer of fluoropyrimidines, a dUTPase inhibitor (TAS-114) in healthy male volunteers. Cancer Chemother Pharmacol. 2014;73:577-583.
22. Hu C-M, Yeh M-T, Tsao N, et al. Tumor cells require thymidylate kinase to prevent dUTP incorporation during DNA repair. Cancer Cell. 2012;22:36-50.
23. Liu Y, Marks K, Cowley GS, et al. Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1- mutant lung cancer. Cancer Discov. 2013;3:870-879.
24. Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo[2,3-d]py- rimidine-based antifolate that inhibits multiple folate-requiring en- zymes. Cancer Res. 1997;57:1116-1123.
25. Shih C, Habeck LL, Mendelsohn LG, Chen VJ, Schultz RM. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv Enzyme Regul. 1998;38:135-152.
26. Adjei AA. Pemetrexed (Alimta): a novel multitargeted antifolate agent. Expert Rev Anticancer Ther. 2003;3:145-156.
27. Bernstock JD, Alva E, Cohen JL, et al. Treatment of pediatric high- grade central nervous system tumors with high-dose methotrexate in combination with multiagent chemotherapy: a single-institution experience. Pediatr Blood Cancer. 2019;18:e28119.
28. Huang Z, Tong H-F, Li Y, et al. Effect of the polymorphism of folyl- polyglutamate synthetase on treatment of high-dose methotrex- ate in pediatric patients with acute lymphocytic leukemia. Med Sci Monit. 2016;22:4967-4973.
29. Walling J. From methotrexate to pemetrexed and beyond. A re- view of the pharmacodynamic and clinical properties of antifolates. Invest New Drugs. 2006;24:37-77.
30. Triarico S, Maurizi P, Mastrangelo S, Attinà G, Capozza MA, Ruggiero A. Improving the brain delivery of chemotherapeutic drugs in child- hood brain tumors. Cancers (Basel). 2019;11:824.
31. Matthay KK, Brisse H, Couanet D, et al. Central nervous system metastases in neuroblastoma: radiologic, clinical, and biologic fea- tures in 23 patients. Cancer. 2003;98:155-165.
32. Jackman AL, Boyle FT, Harrap KR. Tomudex (ZD1694): from con- cept to care, a programme in rational drug discovery. Invest New Drugs. 1996;14:305-316.
33. Kabeshima Y, Kubota T, Watanabe M, et al. A potential important role for thymidylate synthetase inhibition on antitumor activity of fluo- ropyrimidine and raltitexed. Anticancer Res. 2002;22:3245-3252.
34. Qiu C, Li Y, Liang X, et al. A study of peritoneal metastatic xenograft model of colorectal cancer in the treatment of hyperthermic intra- peritoneal chemotherapy with Raltitrexed. Biomed Pharmacother. 2017;92:149-156.
35. van Triest B, Pinedo HM, van Hensbergen Y, et al. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase in- hibitors, in 13 nonselected colon cancer cell lines. Clin Cancer Res. 1999;5:643-654.
36. Zarzosa P, Navarro N, Giralt I, et al. Patient-derived xenografts for childhood solid tumors: a valuable tool to test new drugs and per- sonalize treatments. Clin Transl Oncol. 2017;19:44-50.
37. Tentler JJ, Tan AC, Weekes CD, et al. Patient-derived tumour xe- nografts as models for oncology drug development. Nat Rev Clin Oncol. 2012;9:338-350.